Adjuvant Osimertinib Delivers Unprecedented 8-Year Overall Survival Benefit in Resected EGFR-Mutated NSCLC
核心洞察
Updated ADAURA Phase III data show 79% of adjuvant osimertinib-treated patients with Stage IB-IIIA EGFR (搜索)-mutated NSCLC alive at eight years versus 64% on placebo.
In the primary Stage II-IIIA population, eight-year overall survival was 74% with osimertinib versus 58% with placebo, a 16-percentage-point difference.
Osimertinib reduced the risk of death by 48% in the overall population (HR 0.52; 95% CI 0.39-0.71) and 47% in the primary population (HR 0.53; 95% CI 0.38-0.75).
Adjuvant osimertinib (TAGRISSO) achieved an unprecedented eight-year overall survival benefit in patients with completely resected, early-stage EGFR (搜索)-mutated non-small cell lung cancer (搜索) (NSCLC), according to updated exploratory results from the Phase III ADAURA trial. The findings, presented during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea, and simultaneously published in the Journal of Thoracic Oncology, represent the longest survival ever reported in a global Phase III trial in this setting.
In the overall Stage IB-IIIA population, 79% of patients who received adjuvant osimertinib were estimated to be alive at eight years, compared with 64% of those who received placebo — a 15-percentage-point difference. Osimertinib was associated with a 48% reduction in the risk of death in this population (HR 0.52; 95% CI 0.39-0.71).
Among patients with Stage II-IIIA disease, which constituted the trial's primary population, the estimated eight-year overall survival rate was 74% with osimertinib versus 58% with placebo, a 16-percentage-point difference. The risk of death was reduced by 47% (HR 0.53; 95% CI 0.38-0.75). The overall survival benefit was observed across predefined patient subgroups and remained consistent with the previously reported planned final overall survival analysis.
Benefit Persists Despite High Crossover
Roy S. Herbst, MD, PhD, Director of Dartmouth Cancer Center and principal investigator of ADAURA, highlighted the magnitude of the survival difference despite patients initially assigned to placebo being able to receive osimertinib after disease recurrence.
"These ADAURA findings show patients continue to experience meaningful, long-term benefit following early intervention with adjuvant osimertinib," Herbst said. He also emphasized the importance of identifying EGFR (搜索) mutations at diagnosis to ensure eligible patients can access the therapy.
Herbst further characterized the results as establishing a new paradigm: "This is the first study to establish the new paradigm that bringing the best targeted drugs to patients with earlier-stage disease can delay progression and improve survival. We have come such a long way in the 30 years since EGFR (搜索) inhibitors were first introduced into clinical practice, and this is great news for our patients."
Susan Galbraith, Executive Vice President, Oncology Haematology R&D at AstraZeneca, said the results represented another long-term milestone for ADAURA, noting that nearly four in five patients treated with adjuvant osimertinib were alive eight years after randomization. She said the findings further support early treatment and the role of osimertinib in EGFR (搜索)-mutated lung cancer, reinforcing it as the adjuvant standard of care and backbone therapy across disease stages.
Trial Design and Long-Term Follow-Up
ADAURA (NCT02511106) is a global, randomized, double-blind, placebo-controlled Phase III trial evaluating adjuvant osimertinib in patients with completely resected Stage IB-IIIA EGFR (搜索)-mutated NSCLC, with or without prior adjuvant chemotherapy. A total of 682 patients were enrolled at more than 200 centers across more than 20 countries and randomized to receive osimertinib 80 mg once daily or placebo for up to three years, or until disease recurrence or another discontinuation criterion was met. Adjuvant chemotherapy was permitted.
The primary endpoint was disease-free survival in patients with Stage II-IIIA disease. Key secondary endpoints included disease-free survival in the overall Stage IB-IIIA population and overall survival. All patients had already had the opportunity to complete three years of study treatment before this long-term exploratory analysis.
For the new exploratory analysis, the data cutoff was May 4, 2026. Complete or partial extended survival information was available for approximately 77% of patients who were still alive at the time of the previous final overall survival analysis. For 127 patients without additional survival information, survival times remained censored at their previously recorded time points.
The eight-year results extend earlier ADAURA findings. In the planned final overall survival analysis published in The New England Journal of Medicine in 2023, the five-year overall survival rate among patients with Stage IB-IIIA disease was 88% with osimertinib compared with 78% with placebo, corresponding to a 51% reduction in the risk of death. Among patients with Stage II-IIIA disease, five-year overall survival was 85% with osimertinib and 73% with placebo. The new analysis therefore provides longer-term evidence that the separation in overall survival between treatment groups persists years after completion of the planned three-year course of adjuvant therapy.
Safety and Treatment Adherence
Final safety data for ADAURA were collected during the planned final overall survival analysis. According to AstraZeneca, the safety and tolerability profile of osimertinib remained consistent with its established profile, with no new safety signals identified.
Separate real-world evidence presented at WCLC 2026 evaluated US patients with Stage I-IIIA EGFR (搜索)-mutated NSCLC receiving adjuvant osimertinib. According to AstraZeneca, discontinuing treatment before completing the established three-year course was associated with more than twice the risk of disease recurrence or death.
Three years of adjuvant osimertinib is the standard of care in this setting. The findings add to the long-term ADAURA data supporting molecular testing for EGFR (搜索) mutations in patients with resectable NSCLC and the use of targeted adjuvant therapy in eligible patients.